About Our Program
The Phase II–IV Oncology Research Program at the HonorHealth Research Institute is designed to advance promising cancer therapies from early signal‑seeking studies to pivotal trials supporting regulatory submission and clinical adoption. This program focuses on evaluating the safety, efficacy, and optimal use of innovative therapeutic strategies in multiple disciplines of cancer care. Through this integrated Phase II–IV framework, the Research Institute seeks to accelerate the translation of cutting‑edge cancer research into tangible therapeutic advancements, improving survival outcomes and quality of life for patients facing cancer. Having developed a foundation in gynecologic oncology, the program’s recent expansion includes a broader network of collaborating oncologists holds promise to further enhance patient access, accelerate trial enrollment, and strengthen the diversity of patient participation.
Phase II-IV Oncology Research Cancer Facts and Figures
In 2021, the global incidence of cervical, ovarian, and uterine cancer was 667,430, 298,880, and 473,610, respectively.
In 2021, the global deaths for cervical, ovarian, and uterine cancer were 296,670, 185,610, and 97,670, respectively.
As of February 2026, there are 28 active studies for gynecologic cancers aimed to enhance clinical outcomes and deliver more targeted, effective care for patients facing ovarian, endometrial, cervical, and other gynecologic malignancies.